Alirocumab and cardiovascular outcomes after acute coronary syndrome

ODYSSEY OUTCOMES Committees and Investigators

Research output: Contribution to journalArticle

232 Citations (Scopus)

Abstract

BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-highdensity lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group). CONCLUSIONS Among patients who had a previous acute coronary syndrome and who were receiving highintensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.

Original languageEnglish (US)
Pages (from-to)2097-2107
Number of pages11
JournalNew England Journal of Medicine
Volume379
Issue number22
DOIs
StatePublished - Nov 29 2018

Fingerprint

Acute Coronary Syndrome
Placebos
Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
alirocumab
Confidence Intervals
Maximum Tolerated Dose
Unstable Angina
Apolipoproteins B
Coronary Disease
Hospitalization
Therapeutics
Stroke
Myocardial Infarction
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

ODYSSEY OUTCOMES Committees and Investigators. / Alirocumab and cardiovascular outcomes after acute coronary syndrome. In: New England Journal of Medicine. 2018 ; Vol. 379, No. 22. pp. 2097-2107.
@article{05fbda67ee904184905586989aed6fe3,
title = "Alirocumab and cardiovascular outcomes after acute coronary syndrome",
abstract = "BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-highdensity lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5{\%}) in the alirocumab group and in 1052 patients (11.1{\%}) in the placebo group (hazard ratio, 0.85; 95{\%} confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5{\%}) in the alirocumab group and 392 patients (4.1{\%}) in the placebo group died (hazard ratio, 0.85; 95{\%} CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8{\%} in the alirocumab group vs. 2.1{\%} in the placebo group). CONCLUSIONS Among patients who had a previous acute coronary syndrome and who were receiving highintensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.",
author = "{ODYSSEY OUTCOMES Committees and Investigators} and Schwartz, {G. G.} and Steg, {P. G.} and M. Szarek and Bhatt, {D. L.} and Bittner, {V. A.} and R. Diaz and Edelberg, {J. M.} and Goodman, {S. G.} and C. Hanotin and Harrington, {R. A.} and Jukema, {J. W.} and G. Lecorps and Mahaffey, {K. W.} and A. Moryusef and R. Pordy and K. Quintero and Roe, {M. T.} and Sasiela, {W. J.} and Tamby, {J. F.} and P. Tricoci and White, {H. D.} and Zeiher, {A. M.} and Schiavi, {L. B.} and M. Garrido and Alvarisqueta, {A. F.} and Sassone, {S. A.} and Bordonava, {A. P.} and {Alves De Lima}, {A. E.} and Schmidberg, {J. M.} and Duronto, {E. A.} and Caruso, {O. C.} and Novaretto, {L. P.} and Hominal, {M. A.} and Monta{\~n}a, {O. R.} and A. Caccavo and {Gomez Vilamajo}, {O. A.} and Lorenzatti, {A. J.} and Cartasegna, {L. R.} and Paterlini, {G. A.} and Mackinnon, {I. J.} and Caime, {G. D.} and M. Amuchastegui and Codutti, {O. R.} and Jure, {H. O.} and Bono, {J. O.E.} and Hrabar, {A. D.} and Vallejos, {J. A.} and {Ahuad Guerrero}, {R. A.} and F. Novoa and Robert Fishberg",
year = "2018",
month = "11",
day = "29",
doi = "10.1056/NEJMoa1801174",
language = "English (US)",
volume = "379",
pages = "2097--2107",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

ODYSSEY OUTCOMES Committees and Investigators 2018, 'Alirocumab and cardiovascular outcomes after acute coronary syndrome', New England Journal of Medicine, vol. 379, no. 22, pp. 2097-2107. https://doi.org/10.1056/NEJMoa1801174

Alirocumab and cardiovascular outcomes after acute coronary syndrome. / ODYSSEY OUTCOMES Committees and Investigators.

In: New England Journal of Medicine, Vol. 379, No. 22, 29.11.2018, p. 2097-2107.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alirocumab and cardiovascular outcomes after acute coronary syndrome

AU - ODYSSEY OUTCOMES Committees and Investigators

AU - Schwartz, G. G.

AU - Steg, P. G.

AU - Szarek, M.

AU - Bhatt, D. L.

AU - Bittner, V. A.

AU - Diaz, R.

AU - Edelberg, J. M.

AU - Goodman, S. G.

AU - Hanotin, C.

AU - Harrington, R. A.

AU - Jukema, J. W.

AU - Lecorps, G.

AU - Mahaffey, K. W.

AU - Moryusef, A.

AU - Pordy, R.

AU - Quintero, K.

AU - Roe, M. T.

AU - Sasiela, W. J.

AU - Tamby, J. F.

AU - Tricoci, P.

AU - White, H. D.

AU - Zeiher, A. M.

AU - Schiavi, L. B.

AU - Garrido, M.

AU - Alvarisqueta, A. F.

AU - Sassone, S. A.

AU - Bordonava, A. P.

AU - Alves De Lima, A. E.

AU - Schmidberg, J. M.

AU - Duronto, E. A.

AU - Caruso, O. C.

AU - Novaretto, L. P.

AU - Hominal, M. A.

AU - Montaña, O. R.

AU - Caccavo, A.

AU - Gomez Vilamajo, O. A.

AU - Lorenzatti, A. J.

AU - Cartasegna, L. R.

AU - Paterlini, G. A.

AU - Mackinnon, I. J.

AU - Caime, G. D.

AU - Amuchastegui, M.

AU - Codutti, O. R.

AU - Jure, H. O.

AU - Bono, J. O.E.

AU - Hrabar, A. D.

AU - Vallejos, J. A.

AU - Ahuad Guerrero, R. A.

AU - Novoa, F.

AU - Fishberg, Robert

PY - 2018/11/29

Y1 - 2018/11/29

N2 - BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-highdensity lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group). CONCLUSIONS Among patients who had a previous acute coronary syndrome and who were receiving highintensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.

AB - BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-highdensity lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group). CONCLUSIONS Among patients who had a previous acute coronary syndrome and who were receiving highintensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.

UR - http://www.scopus.com/inward/record.url?scp=85057337718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057337718&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1801174

DO - 10.1056/NEJMoa1801174

M3 - Article

VL - 379

SP - 2097

EP - 2107

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -